Introduction
Multiple myeloma (MM) is a significant health concern, with increasing incidence rates in China. Despite advancements in treatment, many patients become refractory to initial therapies, highlighting the need for new effective treatments. Teclistamab, a B-cell maturation antigen-directed bispecific antibody, has shown promise in treating triple-class exposed relapsed/refractory multiple myeloma (RRMM).
Methods
In the MajesTEC-1 China cohort study, patients received teclistamab 1.5 mg/kg subcutaneously weekly, with the option to switch to less frequent dosing upon continued response. The study aimed to evaluate the efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with RRMM.
Results
The study included 26 patients with a median age of 66 years and a median of five prior lines of therapy. The overall response rate was 76.9%, with 57.7% achieving a complete response or better. Median duration of response, progression-free survival, and overall survival were not reached, indicating durable responses. The safety profile was consistent with previous studies, with infections being the most common adverse event. However, the incidence of infections decreased over time, and no discontinuations due to adverse events were reported.
Conclusions
Teclistamab demonstrated efficacy and safety profiles in Chinese patients with RRMM that were consistent with the pivotal cohort, supporting its use as a promising treatment option. The study highlights the potential of teclistamab to address the unmet clinical need in Chinese patients with RRMM, offering deep and durable responses with a manageable safety profile.
